Machine Learning for PK/PD Modeling in Drug Development
Pharmacometricians can use machine learning for PK/PD modeling to help them characterize the safety and…
Danielle Pillsbury2025年3月4日
How the US FDA MIDD paired pilot program helps sponsors
2025年2月28日 For the past couple of decades, leading American institutions, pharmaceutical and biotechnology…
Danielle Pillsbury2025年2月28日
Gain Nonclinical Drug Safety Insights with Real-Time Data Analysis
2025年2月24日 Efficient drug development relies on informed decision-making. For toxicologists, having timely access…
Danielle Pillsbury2025年2月24日
Measuring metabolites in index clinical DDI studies
2025年2月7日A key drug development safety consideration is whether the drug candidate will interact…
Danielle Pillsbury2025年2月7日
Key development considerations for cell therapies
2024年12月5日 What is a “cell therapy”? Nearly every recent oncology clinical conference has…
Becca Bucci2024年12月5日
PBPK Modeling to Support Bioequivalence & Generic Product Approvals
Physiologically-based pharmacokinetic modeling can be used to support bioequivalence (BE) assessment of complex and locally…
Jim Gallagher2024年11月12日
The Future is Now: Virtual Clinical Trials Transforming Drug Development
Welcome to the forefront of drug development innovation! The drug development landscape is rapidly evolving,…
Danielle Pillsbury2024年6月4日
Phoenix UGM 2024: A Day of Innovation and Collaboration
The Phoenix UGM featured industry expert insights, peer networking, and glimpses into the latest PK/PD…
Jim Gallagher2024年5月31日
